Astellas : News Releases

PADCEVTM Plus KEYTRUDATM Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

17 days ago

PADCEV plus KEYTRUDA is the first and only regimen to improve survival...

Posted Financial Results for Q1 YTD/FY2025

about 1 month ago

Astellas Announces a Partnership with the “Korea Institute of Startup and Entrepreneurship Development”, an Umbrella Organization of a Korean Government Agency, for the Operation of the“Partnership with Global Companies Program”

about 1 month ago

- Supporting Korean Startups’ Drug Discovery Research and Global Expansion -- First...

Sales of IZERVAY™ (Preliminary Figures)

about 2 months ago

TOKYO, July 10, 2025 – Astellas Pharma Inc. (TSE: 4503, President and...

Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan

3 months ago

Tokyo, 13 June 2025—Mitsubishi Research Institute, Inc. (“MRI”) and Astellas Pharma Inc...

Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2

3 months ago

- Agreement grants Astellas exclusive worldwide rights (excluding China’s mainland, Hong Kong...

Posted Notice of Convocation of the 20th Term Annual Shareholders Meeting

3 months ago

Shaping the Future with Pompe Patients

3 months ago

Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer

3 months ago

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide)...

Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting

3 months ago

16 abstracts, including two oral presentations, feature new clinical data from Astellas’...

Addressing Global Health Challenges

3 months ago

Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme and Performance-linked Stock Delivery Scheme for the Domestic and Global Astellas Group Executives

4 months ago

TOKYO, May 15, 2025 – Astellas Pharma Inc. (TSE: 4503, President and...